Thông tin thuốc gốc
Chỉ định và Liều dùng
Cancer, pancreatic, Gastric cancer, Head and neck cancer, Metastatic breast cancer, Non-small cell lung cancer, Prostate cancer
Adult: Dosage requirement is individualised according to local protocols (refer to detailed product guideline). Usual dose: 10-20 mg/m2 may be repeated at intervals of 6-8 weeks if blood counts permit and may be adjusted according to previous haematological response. Alternatively, 4-10 mg (0.06-0.15 mg/kg) at 1-6 weekly intervals.

Superficial bladder tumours
Adult: Usual dose: 20-40 mg instilled once weekly or 3 times a week for a total of 20 doses. Retain solution in the bladder for at least 1 hour by rotating dose contact with all areas of the bladder urothelium every 15 minutes. Alternatively, 4-10 mg (0.06-0.15 mg/kg) instilled once weekly or 3 times a week. For prophylaxis of recurrent cases: 20 mg every 2 weeks or 40 mg monthly or 3-monthly.

Adjunct in ophthalmic surgery
Adult: As 0.2 mg/mL solution: Apply via saturated sponges to the surgical site of glaucoma filtration surgery. Keep the sponges on the treatment area for 2 minutes.
Hướng dẫn pha thuốc
Dilute with sterile water for inj to a final concentration of 0.5 mg/mL. May further dilute in 0.9% NaCl or Na lactate to a concentration of 0.02-0.04 mg/mL.
Reconstitute 0.2 mg with 1 mL of sterile water for inj, then shake to dissolve. Allow to stand at room temperature until the product has dissolved into solution.
Tương kỵ
Incompatible with highly acidic substances.
Chống chỉ định
Hypersensitivity to mitomycin. Thrombocytopenia, coagulation disorders, increased bleeding tendency, acute infections, serum creatinine >1.7 mg/dL. Pregnancy and lactation.
Thận trọng
Patient with bone marrow suppression (platelet count <100,000/mm3, WBC <4,000/mm3, or progressive decline in either), infections (e.g. varicella infection). Phakic patients (ophthalmic). Patients receiving blood product transfusions. Renal and hepatic impairment.
Tác dụng không mong muốn
Significant: Bone marrow suppression (e.g. leucopenia, thrombocytopenia), renal toxicity, local ulceration and cellulitis (IV), shock or anaphylactoid reaction (e.g. itching, rash, dyspnoea, flushing), neurologic abnormalities. Ophthalmic: Corneal or scleral damage (when given in doses >0.2 mg/mL or used for longer than 2 minutes), post-operative hypotony.
Eye disorders: Retinal vein occlusion, conjunctival necrosis, haemorrhage (retinal, subconjunctival, suprachoroidal, vitreal), bleb-related infection.
Gastrointestinal disorders: Nausea, vomiting, diarrhoea, stomatitis.
General disorders and admin site conditions: Malaise, pyrexia, asthenia.
Injury, poisoning and procedural complications: Vascular pain, phlebitis, thrombus, induration or necrosis at the inj site.
Investigations: Increased serum creatinine.
Metabolism and nutrition disorders: Anorexia.
Renal and urinary disorders: Intravesical: Cystitis, bladder fibrosis or contracted bladder (e.g. pollakiuria, dysuria), calcinosis.
Skin and subcutaneous tissue disorders: Palmar plantar erythrodysaesthesia, alopecia, pruritus, rash.
Vascular disorders: Hypertension.
Potentially Fatal: Haemolytic-uraemic syndrome, sepsis, pulmonary toxicities (e.g. pulmonary oedema, interstitial pneumonia, pulmonary fibrosis, pulmonary hypertension, pulmonary venoocclusive disease).
Thông tin tư vấn bệnh nhân
This drug may cause weakness and lethargy, if affected, do not drive or operate machinery.
Chỉ số theo dõi
Monitor renal function (e.g. serum creatinine) prior to treatment and after each course, CBC with differential during therapy and for ≥8 weeks following therapy; liver and pulmonary function tests frequently.
Quá liều
Symptoms: Increased adverse effects such as fever, nausea, vomiting, myelosuppression. Management: Supportive treatment.
Tương tác
Concomitant use with other chemotherapy agents (e.g. vinca alkaloids) may enhance adverse effects e.g. pulmonary toxicity, bone marrow suppression.
Tác dụng
Description: Mitomycin, a highly toxic antineoplastic antibiotic, selectively inhibits the synthesis of deoxyribonucleic acid (DNA) by alkylating DNA to produce DNA cross-linking (primarily with guanine and cytosine pairs). It also suppresses cellular ribonucleic acid (RNA)  synthesis at high concentrations. Although it is not a cell cycle-specific agent, it is most active in the late G1 and early S phases.
Distribution: Widely distributed.
Metabolism: Metabolised primarily in the liver.
Excretion: Mainly via faeces; urine (approx 10%, as unchanged drug).  Terminal half-life: Approx 50 minutes.
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Mitomycin, CID=5746, (accessed on Jan. 22, 2020)

Bảo quản
IV: Store at 25°C. Protect from excessive heat >40°C. Reconstituted solution: Store at room temperature with stability of 7 days or refrigerate at 2-8°C with stability of 14 days. Protect from light. Ophthalmic: Store between 20-25°C. Protect from excessive heat and light. Reconstituted solution is stable for 1 hour at room temperature. This is a cytotoxic drug. Any unused portions should be disposed of in accordance with local requirements.
Phân loại MIMS
Hóa trị gây độc tế bào
Phân loại ATC
L01DC03 - mitomycin ; Belongs to the class of other cytotoxic antibiotics. Used in the treatment of cancer.
Tài liệu tham khảo
Anon. Mitomycin (Ophthalmic). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 11/09/2019.

Anon. Mitomycin (Systemic). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 11/09/2019.

Buckingham R (ed). Mitomycin. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 11/06/2014.

Mitomycin Injection (West-Ward Pharmaceuticals Corp). DailyMed. Source: U.S. National Library of Medicine. Accessed 11/09/2019.

Mitomycin Powder for Solution for Injection/Infusion (Substipharm Limited). MHRA. Accessed 11/09/2019.

Mitosol Solution (Mobius Therapeutics LLC). DailyMed. Source: U.S. National Library of Medicine. Accessed 11/09/2019.

Mitosol Solution (Mobius Therapeutics, LLC). U.S. FDA. Accessed 11/09/2019.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Mitomycin từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2022 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
  • Mitomycin-C Kyowa
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in